News

Ipsen Expands Oncology Portfolio with $247 Million Epizyme Acquisition

June 30, 2022

Ipsen will acquire Epizyme, who recently had their lead medicine Tazverik (tazemetostat) approved by FDA for treatment of relapsed or refractory follicular lymphoma.

Inceptor Bio Collaborates with University of Minnesota to Develop Cell Therapy Platform

June 30, 2022

Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.

MilliporeSigma to Supply Lotte Biologics with Biologics Manufacturing Capabilities in US

June 29, 2022

MilliporeSigma and Lotte Group will collaborate on facility design and workforce training for a new biologics business unit in the US.

Avantor Partners with GeminiBio on Custom Hydrated Solutions and Cell Culture Media

June 29, 2022

Under the collaboration, Avantor and GeminiBio will offer custom cGMP solutions to enhance process efficiency and accelerate speed-to-market of novel emerging therapy modalities.

Cosentyx Receives Expanded Approvals in EU for Use in Childhood Arthritic Conditions

June 29, 2022

The European Commission has approved Cosentyx for the treatment of various childhood arthritic conditions.

Xenpozyme Approved by EC for the Treatment of ASMD

June 29, 2022

The European Commission has approved Xenpozyme as the first treatment for ASMD.

FDA Releases Action Plan for Rare Neurodegenerative Diseases

June 29, 2022

The action plan will span over five years and will fulfill a requirement of the Accelerating Access to Critical Therapies for ALS Act.

MilliporeSigma Intensifies Upstream Processing with New BioContinuum Seed Train Platform Offering

June 27, 2022

MilliporeSigma’s new BioContinuum Seed Train Platform offering enables a fully closed bioprocessing environment for both fed-batch and perfusion N-production.

Regulators Seek More Drug Effects Research Related to Pregnancy and Lactation

June 27, 2022

Regulators wish to expand and clarify methods for obtaining information on medicines used by or needed for pregnant and lactating individuals through clinical trials and postapproval studies.

ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs

June 27, 2022

ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.